How to appeal a CareFirst BCBS compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Cited policy: Anthem / BCBSA Drug Coverage Policy: Compounded Products

Compounded medication covered when commercial alternative inappropriate; off-label clinical use requires peer-reviewed evidence; pharmacy must comply with USP 795/797/800 and DQSA §503A or §503B.

How CareFirst BCBS denies compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics — and how to counter it

Where CareFirst BCBS pushes back: 1) Compounded ketamine experimental for mental health; 2) Spravato (esketamine) is FDA-approved alternative; 3) Mental-health pharmacy benefit excludes compounded drugs.

Counter-arguments that hold up: Cite Wilkinson Am J Psychiatry 2017 review on oral / sublingual ketamine in treatment-resistant depression; cite Andrade J Clin Psychiatry 2017. Document failed standard antidepressants (SSRIs, SNRIs, augmentation) per STAR*D / Maudsley framework. Spravato (esketamine intranasal) FDA-approved 2019 is the comparator commercial product — when Spravato is unavailable due to access, REMS-prescriber location barrier, cost-share unaffordable, or in-clinic-administration impractical, compounded sublingual / intranasal ketamine is medically necessary. Submit pharmacy 503A + USP 795 compliance + Schedule III handling. Ketamine HCl is on the FDA 503A bulks list Category 1.

What CareFirst BCBS typically denies for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• BHRT compounded
• Bi-Est cream
• Compounded testosterone
• Compounded progesterone
• Low-dose naltrexone (LDN)
• Compounded ketamine

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.